PMID- 36787524
OWN - NLM
STAT- MEDLINE
DCOM- 20230216
LR  - 20230224
IS  - 1936-2692 (Electronic)
IS  - 1088-0224 (Linking)
VI  - 29
IP  - 2 Suppl
DP  - 2023 Feb
TI  - Suprachoroidal triamcinolone acetonide injectable suspension for macular edema 
      associated with noninfectious uveitis: an in-depth look at efficacy and safety.
PG  - S19-S28
LID - 10.37765/ajmc.2023.89324 [doi]
AB  - Patients with macular edema (ME) associated with uveitis (UME) are at risk for 
      vision loss and decreased quality of life, and they often experience high health 
      care costs and rates of workforce absenteeism. Systemically or locally delivered 
      corticosteroids are the mainstay of treatment for UME. Although traditional 
      corticosteroid treatments may demonstrate high levels of efficacy, systemic 
      delivery carries the risk of potentially serious systemic adverse effects (AEs), 
      and standard local modes of delivery may be associated with low bioavailability 
      in posterior ocular tissues and steroid-associated AEs due to anterior ocular 
      tissue exposure. Drug injection into the suprachoroidal space (SCS) allows for 
      targeted delivery to chorioretinal tissues with high bioavailability in the 
      posterior segment, as well as for inherent drug sequestration away from the 
      anterior segment, which may lower the risk of AEs associated with anterior tissue 
      exposure to steroids. A novel triamcinolone acetonide (TA) injectable suspension 
      formulated for administration to the SCS, SCS-TA (Xipere(R); Bausch + Lomb), 
      received FDA approval in 2021 for the treatment of UME. It is administered via 
      the SCS Microinjector(R) (Clearside Biomedical, Inc), a device specifically 
      designed for SCS delivery of ocular therapeutics. This approval was based on 
      results from the phase 3 PEACHTREE clinical trial (NCT02595398) that demonstrated 
      the clinical efficacy-including significantly increased visual acuity and 
      decreased central subfield thickness-and safety of SCS-TA in patients with UME. 
      Results from this trial, as well as from its long-term observational extension 
      (MAGNOLIA; NCT02952001) and an open-label safety study (AZALEA; NCT03097315), 
      support the possibility that treatment with SCS-TA may address the burden of 
      disease in patients with UME.
FAU - Yeh, Steven
AU  - Yeh S
AD  - Truhlsen Eye Institute, 3902 Leavenworth Street. Omaha, NE 68105. syeh@unmc.edu.
FAU - Ciulla, Thomas
AU  - Ciulla T
LA  - eng
SI  - ClinicalTrials.gov/NCT03097315
SI  - ClinicalTrials.gov/NCT02952001
SI  - ClinicalTrials.gov/NCT02595398
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Manag Care
JT  - The American journal of managed care
JID - 9613960
RN  - F446C597KA (Triamcinolone Acetonide)
RN  - 0 (Glucocorticoids)
MH  - Humans
MH  - Triamcinolone Acetonide/adverse effects
MH  - Glucocorticoids/adverse effects
MH  - *Macular Edema/etiology/complications
MH  - Quality of Life
MH  - Choroid
MH  - *Uveitis/complications/drug therapy
MH  - Treatment Outcome
EDAT- 2023/02/15 06:00
MHDA- 2023/02/17 06:00
CRDT- 2023/02/14 16:16
PHST- 2023/02/14 16:16 [entrez]
PHST- 2023/02/15 06:00 [pubmed]
PHST- 2023/02/17 06:00 [medline]
AID - 89324 [pii]
AID - 10.37765/ajmc.2023.89324 [doi]
PST - ppublish
SO  - Am J Manag Care. 2023 Feb;29(2 Suppl):S19-S28. doi: 10.37765/ajmc.2023.89324.